drugset
drugset / Trial / NCT05072535

A Study to Evaluate Relative Bioavailability and Food-Effect of HA121-28 Tablet B in Healthy Subjects

NCT05072535 ↗

Phase 1 Completed 40 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
RandomizedCrossoverOpen-labelBasic science

Summary

The study will be divided into 2 parts. The first part is a relative bioavailability study of HA121-28 tablet A and HA121-28 tablet B, and the second part is a food effect study of HA121-28 tablet B. Both Parts are single-dose, randomized, open-label, two-period crossover study to evaluate relative bioavailability HA121-28 tablet B in healthy subjects and the effect of food on pharmacokinetic profile of HA121-28 tablet B, respectively.

Timeline

Start
2021-10-08
Primary completion
2021-12-19
Completion
2022-03-03

Drugs

EvaluationDrugModalityDoseRoute
Subject HA121-28 Unknown 200 mg —

Indications

No indication recorded.